| Literature DB >> 29186155 |
Megan M Campbell1, Ezra Susser2, Sumaya Mall1, Sibonile G Mqulwana1, Michael M Mndini1, Odwa A Ntola1, Mohamed Nagdee3, Zukiswa Zingela4, Stephanus Van Wyk4, Dan J Stein5.
Abstract
Obtaining informed consent is a great challenge in global health research. There is a need for tools that can screen for and improve potential research participants' understanding of the research study at the time of recruitment. Limited empirical research has been conducted in low and middle income countries, evaluating informed consent processes in genomics research. We sought to investigate the quality of informed consent obtained in a South African psychiatric genomics study. A Xhosa language version of the University of California, San Diego Brief Assessment of Capacity to Consent Questionnaire (UBACC) was used to screen for capacity to consent and improve understanding through iterative learning in a sample of 528 Xhosa people with schizophrenia and 528 controls. We address two questions: firstly, whether research participants' understanding of the research study improved through iterative learning; and secondly, what were predictors for better understanding of the research study at the initial screening? During screening 290 (55%) cases and 172 (33%) controls scored below the 14.5 cut-off for acceptable understanding of the research study elements, however after iterative learning only 38 (7%) cases and 13 (2.5%) controls continued to score below this cut-off. Significant variables associated with increased understanding of the consent included the psychiatric nurse recruiter conducting the consent screening, higher participant level of education, and being a control. The UBACC proved an effective tool to improve understanding of research study elements during consent, for both cases and controls. The tool holds utility for complex studies such as those involving genomics, where iterative learning can be used to make significant improvements in understanding of research study elements. The UBACC may be particularly important in groups with severe mental illness and lower education levels. Study recruiters play a significant role in managing the quality of the informed consent process.Entities:
Mesh:
Year: 2017 PMID: 29186155 PMCID: PMC5707000 DOI: 10.1371/journal.pone.0188466
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The forward- and back-translation of the UBACC.
| Original UBACC English version | UBACC Xhosa version | UBACC English back-translation |
|---|---|---|
| 1. What is the purpose of the study that was just described to you? | 1. Yintoni injongo yoluphondo lwenzziwayo ndigqiba ukukucacisela ngalo? | 1. What is the purpose of the investigation that I have just explained to you? |
| 2. What makes you want to consider participating in this study? | 2. Yintoni ekwenze ukuba ufune ukuthabatha inxaxheba koluphando? | 2. What made you want to take part in this investigation? |
| 3. Do you believe this is primarily research or primarily treatment? | 3. Ingaba ucinga ukuba olu luphando okanye lunyango? | 3. Do you think this is an investigation or treatment? |
| 4. Do you have to be in this study if you do not want to participate? | 4. Ucinga ukuba kunyanzelekile na ukuba ube koluphando nokuba awufuni? | 4. Do you think you must take part in this investigation even if you don’t want to? |
| 6. If you participate in this study, what are some of the things that you will be asked to do? | 6. Ukuba uthe wathatha inxaxheba koluphando zeziphi ezinye zezinto ozakucelwa uzenze? | 6. If you are taking part in this investigation what are the things that you will be asked to do? |
Sample information.
| Variables | Categories/Labels | Frequencies (%) |
|---|---|---|
| Case | 528 (50%) | |
| Control | 528 (50%) | |
| Male | 946 (89.6%) | |
| Female | 110 (10.4%) | |
| Younger (20–39) | 674 (63.8%) | |
| Older (40–59) | 382 (36.2%) | |
| Primary (≤Grade 7) | 336 (31.8%) | |
| Secondary (≥Grade 8) | 720 (68.2%) | |
| Western Cape | 276 (26.1%) | |
| Eastern Cape | 780 (73.9%) | |
| A | 311 (29.5%) | |
| B | 285 (27.0%) | |
| C | 198 (18.8%) | |
| D | 116 (11.0%) | |
| E | 146 (13.8%) |
Comparison of UBACC mean scores for cases and controls across UBACC trials 1 and 2.
| Trial 1 M(SD) | Trial 2 | Mean difference | Correlation | P-value | Effect size | |
|---|---|---|---|---|---|---|
| 13.66 (3.5) | 17.69 (2.1) | 4.03 (2.5) | 0.700 | <0.000 | 1.240 | |
| 15.41 (3.0) | 18.59 (1.7) | 3.18 (2.2) | 0.695 | <0.000 | 1.128 |
Fig 1Changes in UBACC means across trials 1 and 2.
Linear regression analysis of hypothesized predictors of decisional capacity using the UBACC.
| Model | Unstandardized co-efficient Beta | Std. Error | P-value | CI:95% | |
|---|---|---|---|---|---|
| 10.345 | 0.494 | <0.000 | 9.376–11.314 | ||
| 1.541 | 0.199 | <0.000 | 1.151–1.931 | ||
| 0.027 | 0.007 | <0.000 | 0.014–0.040 | ||
| 0.643 | 0.293 | 0.028 | 0.069–1.218 | ||
| 0.710 | 0.189 | <0.000 | 0.338–1.082 | ||
| 1.372 | 0.194 | <0.000 | 0.992–1.752 | ||
| 0.186 | 0.206 | 0.368 | -0.219–0.590 | ||
| B | 2.403 | 0.235 | <0.000 | 1.942–2.864 | |
| C | 2.426 | 0.262 | <0.000 | 1.911–2.941 | |
| D | 3.405 | 0.327 | <0.000 | 2.762–4.047 | |
| E | 1.628 | 0.301 | <0.000 | 1.038–2.218 |
* Reference Group